Clinical study of pemetrexed combined with carboplatin as the first-line treatment of senile patients with advanced non-squamous non-small cell lung cancer

Objective To evaluate the curative effect and toxicity of pemetrexed combined with carboplatin as the first-line treatment of senile patient with advanced non-squamous non-small cell lung cancer.Methods 92 patients with advanced non-squamous non-small cell lung cancer were divided into two groups.The PC group(42 cases) were treated with pemetrexed combined with carboplatin,and the GC group(50 cases) were treated with gemcitabine combined with carboplatin.Results The disease control rate was 73.8% in the PC group and 70.2% in the GC group(P0.05),but the incidence of side effects was significantly lower in the PC group than in the GC group.Conclusion Pemetrexed combined with carboplatin has the similar curative effect with gemcitabine combined with carboplatin in treatment of senile patient with advanced non-squamous non-small cell lung cancer,but it has less side effects and better tolerance than gemcitabine combined with carboplatin.